8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 19, 2006)

Filed July 19, 2006For Securities:ABT

Summary

Abbott Laboratories filed an 8-K on July 19, 2006, to report its second-quarter 2006 financial results. The filing primarily serves to provide investors with the company's performance metrics for the quarter. Notably, Abbott Laboratories utilizes and discloses non-GAAP financial measures, such as earnings and diluted earnings per common share, adjusted for specific items like merger-related costs, purchase accounting adjustments, restructuring and impairment charges, litigation charges, and the impact of regulatory changes. Management believes these non-GAAP measures offer a clearer view of ongoing business performance and are used internally for performance monitoring. However, investors are cautioned to consider these alongside traditional GAAP measures.

Key Highlights

  • 1Abbott Laboratories announced its second-quarter 2006 results via an 8-K filing on July 19, 2006.
  • 2The company provided its financial results for the period ending in the second quarter of 2006.
  • 3Abbott Laboratories employs non-GAAP financial measures, including adjusted earnings and adjusted diluted earnings per share.
  • 4These non-GAAP measures exclude items such as merger costs, purchase accounting adjustments, restructuring charges, and litigation expenses.
  • 5Management asserts that these non-GAAP measures enhance the understanding of ongoing business performance.
  • 6Investors are advised to review non-GAAP measures in conjunction with, not as a substitute for, GAAP financial statements.
  • 7The filing includes a press release (Exhibit 99.1) detailing the Q2 2006 results, furnished under Item 2.02.

Frequently Asked Questions

The primary purpose of this 8-K filing is to officially report Abbott Laboratories' financial results for the second quarter of 2006. It includes a press release that details these results.

Non-GAAP financial measures are financial metrics that exclude certain items that are considered unusual or unpredictable, such as merger-related costs, restructuring charges, or litigation expenses. Abbott uses them because management believes they provide a more insightful view of the company's ongoing operational performance, allowing investors to better evaluate the core business.

No, investors are cautioned by Abbott Laboratories to consider these non-GAAP financial measures in addition to, and not as a substitute for, the financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). GAAP measures provide the standard basis for financial reporting.

The filing was signed by Thomas C. Freyman, Executive Vice President, Finance, and Chief Financial Officer, indicating his authorization as per the requirements of the Securities Exchange Act of 1934.